Literature DB >> 10491012

Depressed IL-12-mediated signal transduction in T cells from patients with Sézary syndrome is associated with the absence of IL-12 receptor beta 2 mRNA and highly reduced levels of STAT4.

L C Showe1, F E Fox, D Williams, K Au, Z Niu, A H Rook.   

Abstract

Sézary syndrome (SS) is the leukemic phase of cutaneous T cell lymphoma characterized by the proliferation of clonally derived CD4+ T cells that release cytokines of the Th2 T cell phenotype (IL-4, IL-5, IL-10), whereas Th1 T cell cytokines (IL-2, IFN-gamma) are markedly depressed as is expression of IL-12, a pivotal cytokine for Th1 cell differentiation. Normal Th1 cells express both the beta 1 and beta 2 chains of the IL-12 receptor (IL-12R) and tyrosine phosphorylate STAT4 in response to IL-12. Th2 T cells express only the IL-12R beta 1 and thus do not tyrosine phosphorylate STAT4 in response to IL-12. To determine whether SS cells are Th2-like at the level of IL-12 signal transduction, we analyzed RNA from seven patients for the presence of message for the IL-12R beta 1 and beta 2 genes using RNase protection assays and assessed whether IL-12 induced tyrosine-phosphorylation of STAT4 by immunoblotting. In PBL from six of seven SS patients tested, beta 2 message was expressed at low to undetectable levels and its expression could not be stimulated by either IFN-alpha or IFN- gamma, which stimulated beta 2 expression in control PBL. The absence of beta 2 expression is further supportive evidence for the Th2 lineage of SS cells. However, unlike normal Th2 cells, SS cells also showed severely reduced levels of STAT4, suggesting that they have a depressed response to any inducer of the STAT4 signal transduction pathway, including IFN-alpha. This is the first observation linking STAT4 gene expression with a human disease and suggests that dysregulation of STAT4 expression may be significant to the development and/or progression of SS.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10491012

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  14 in total

Review 1.  Signal transducer and activator of transcription (STAT) signalling and T-cell lymphomas.

Authors:  Tracey J Mitchell; Susan John
Journal:  Immunology       Date:  2005-03       Impact factor: 7.397

2.  Quantitative PCR on 5 genes reliably identifies CTCL patients with 5% to 99% circulating tumor cells with 90% accuracy.

Authors:  Michael Nebozhyn; Andrey Loboda; Laszlo Kari; Alain H Rook; Eric C Vonderheid; Stuart Lessin; Carole Berger; Richard Edelson; Calen Nichols; Malik Yousef; Lalitha Gudipati; Meiling Shang; Michael K Showe; Louise C Showe
Journal:  Blood       Date:  2006-01-10       Impact factor: 22.113

3.  Genetic markers associated with progression in early mycosis fungoides.

Authors:  V E Johnson; E C Vonderheid; A D Hess; C M Eischen; L Y McGirt
Journal:  J Eur Acad Dermatol Venereol       Date:  2013-10-31       Impact factor: 6.166

4.  Synergistic enhancement of cellular immune responses by the novel Toll receptor 7/8 agonist 3M-007 and interferon-γ: implications for therapy of cutaneous T-cell lymphoma.

Authors:  Maria Wysocka; Noor Dawany; Bernice Benoit; Andrew V Kossenkov; Andrea B Troxel; Joel M Gelfand; Michael Kelly Sell; Louise C Showe; Alain H Rook
Journal:  Leuk Lymphoma       Date:  2011-10

5.  Approaches for investigating the extracellular signaling function of ISG15.

Authors:  Caleb D Swaim; Larissa A Canadeo; Jon M Huibregtse
Journal:  Methods Enzymol       Date:  2019-02-01       Impact factor: 1.600

6.  CD164 identifies CD4+ T cells highly expressing genes associated with malignancy in Sézary syndrome: the Sézary signature genes, FCRL3, Tox, and miR-214.

Authors:  Bernice M Benoit; Neha Jariwala; Geraldine O'Connor; Landon K Oetjen; Timothy M Whelan; Adrienne Werth; Andrea B Troxel; Hélène Sicard; Lisa Zhu; Christopher Miller; Junko Takeshita; Daniel W McVicar; Brian S Kim; Alain H Rook; Maria Wysocka
Journal:  Arch Dermatol Res       Date:  2016-10-20       Impact factor: 3.017

Review 7.  Mycosis fungoides and sezary syndrome: an update.

Authors:  Ellen J Kim; Julie Lin; Jacqueline M Junkins-Hopkins; Carmela C Vittorio; Alain H Rook
Journal:  Curr Oncol Rep       Date:  2006-09       Impact factor: 5.075

8.  Analysis of STAT4 expression in cutaneous T-cell lymphoma (CTCL) patients and patient-derived cell lines.

Authors:  Ivan V Litvinov; Brendan Cordeiro; Simon Fredholm; Niels Ødum; Hanieh Zargham; Yuanshen Huang; Youwen Zhou; Kevin Pehr; Thomas S Kupper; Anders Woetmann; Denis Sasseville
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

9.  Deregulation in STAT signaling is important for cutaneous T-cell lymphoma (CTCL) pathogenesis and cancer progression.

Authors:  Elena Netchiporouk; Ivan V Litvinov; Linda Moreau; Martin Gilbert; Denis Sasseville; Madeleine Duvic
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

Review 10.  The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: Current and future approaches.

Authors:  David M Weiner; Joseph S Durgin; Maria Wysocka; Alain H Rook
Journal:  J Am Acad Dermatol       Date:  2020-12-22       Impact factor: 11.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.